The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alters, S. E.
Right arrow Articles by Oi, V. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alters, S. E.
Right arrow Articles by Oi, V. T.

The Journal of Immunology, Vol 144, Issue 12 4587-4592, Copyright © 1990 by American Association of Immunologists

ARTICLES

Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies

SE Alters, K Sakai, L Steinman and VT Oi
Program in Cancer Biology, Stanford University School of Medicine, CA 94305.

A family of rat-mouse chimeric anti-murine CD4 antibodies was used to study the mechanisms of anti-CD4-mediated depletion and immunotherapy. The chimeric antibodies retain identical affinity and specificity as the therapeutically effective prototype antibody, rat GK1.5, but are of different mouse isotypes. GK1.5 gamma 1, GK1.5 gamma 2a, and GK1.5 gamma 2b are significantly more effective at CD4+ cell depletion than rat GK1.5 when low doses of antibody are administered. In contrast, no depletion is seen with GK1.5 gamma 3 at any dose. Depletion of CD4+ cells in vivo is not correlated with either the ability of the antibody to mediate C-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity in vitro, implying that additional antibody-mediated cytotoxic mechanisms occur in vivo. The chimeric antibodies were used to investigate the mechanism of GK1.5-mediated immunotherapy in a prototypic model of T cell-mediated autoimmunity, experimental allergic encephalomyelitis. Mice treated with a single dose of 100 micrograms of either GK1.5, GK1.5 gamma 1, or GK1.5 gamma 2a showed significant recovery within 72 h. In contrast, mice treated with 100 micrograms of GK1.5 gamma 3 showed only marginal improvement within the first 72 h and regressed within 5 days of treatment initiation. These data suggest that anti-CD4-mediated immunotherapy of murine experimental allergic encephalomyelitis is correlated with depletion of CD4+ cells.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
B. Chackerian, M. R. Durfee, and J. T. Schiller
Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model
J. Immunol., May 1, 2008; 180(9): 5816 - 5825.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
L. Steinman
Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year
J. Exp. Med., May 5, 2003; 197(9): 1065 - 1071.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. D. Isaacs
From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies
Rheumatology, July 1, 2001; 40(7): 724 - 738.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. D. Isaacs, J. Greenwood, and H. Waldmann
Therapy with Monoclonal Antibodies. II. The Contribution of Fc{gamma} Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector Function
J. Immunol., October 15, 1998; 161(8): 3862 - 3869.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.